DOI: 10.1515/mr-2023-0071
Biofluid biomarkers for Alzheimer's disease:past,present,and future
Chengyu An1
Huimin Cai2
Ziye Ren1
Xiaofeng Fu1
Shuiyue Quan1
Longfei Jia2
1.Innovation Center for Neurological Disorders and Department of Neurology,Xuanwu Hospital,Capital Medical University,National Clinical Research Center for Geriatric Diseases,Beijing,China2.Innovation Center for Neurological Disorders and Department of Neurology,Xuanwu Hospital,Capital Medical University,National Clinical Research Center for Geriatric Diseases,45 Changchun St.,Beijing 100053,China
摘要：Alzheimer's disease(AD)is a gradually progres-sive neurodegenerative disease with tremendous social and economic burden.Therefore,early and accurate diagnosis is imperative for effective treatment or prevention of the disease.Cerebrospinal fluid and blood biomarkers emerge as favorable diagnostic tools due to their relative accessi-bility and potential for widespread clinical use.This review focuses on the AT(N)biomarker system,which includes biomarkers reflecting AD core pathologies,amyloid deposi-tion,and pathological tau,as well as neurodegeneration.Novel biomarkers associated with inflammation/immunity,synaptic dysfunction,vascular pathology,and α-synuclein-opathy,which might contribute to either the pathogenesis or the clinical progression of AD,have also been discussed.Other emerging candidates including non-coding RNAs,metabolites,and extracellular vesicle-based markers have also enriched the biofluid biomarker landscape for AD.Moreover,the review discusses the current challenges of biofluid biomarkers in AD diagnosis and offers insights into the prospective future development.
机标关键词：alzheimerpresentfuturepastbiofluidbiomarkersdisease
论文发表日期：2024-12-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
英文信息